attentin 20 mg tablett
orifarm ab - dexamfetaminsulfat - tablett - 20 mg - isomalt hjälpämne; dexamfetaminsulfat 20 mg aktiv substans
verzenios
eli lilly nederland b.v. - abemaciclib - bröst-neoplasmer - antineoplastiska medel - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
attentin 20 mg tablett
medartuum ab - dexamfetaminsulfat - tablett - 20 mg - dexamfetaminsulfat 20 mg aktiv substans; isomalt hjälpämne
tenofovirdisoproxil laurus 245 mg filmdragerad tablett
laurus generics gmbh - tenofovirdisoproxilfumarat - filmdragerad tablett - 245 mg - tenofovirdisoproxilfumarat 300 mg aktiv substans; laktosmonohydrat hjälpämne
tenofovirdisoproxil ebb 245 mg filmdragerad tablett
ebb medical ab - tenofovirdisoproxilfumarat - filmdragerad tablett - 245 mg - laktosmonohydrat hjälpämne; tenofovirdisoproxilfumarat 300 mg aktiv substans
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - bröst-neoplasmer - antineoplastiska medel - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatiska neoplasmer - endokrin terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
cresnisol n10 infusionsvätska, lösning
baxter medical ab - alanin; arginin; asparaginsyra; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; leucin; lysinacetat; metionin; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - metionin 3,16 g aktiv substans; fenylalanin 4,39 g aktiv substans; prolin 3,77 g aktiv substans; serin 2,5 g aktiv substans; treonin 3,16 g aktiv substans; tryptofan 1,06 g aktiv substans; tyrosin 0,16 g aktiv substans; valin 4,05 g aktiv substans; lysinacetat 7,02 g aktiv substans; alanin 9,16 g aktiv substans; arginin 6,2 g aktiv substans; asparaginsyra 1,83 g aktiv substans; glutaminsyra 3,16 g aktiv substans; glycin 4,39 g aktiv substans; histidin 3,77 g aktiv substans; isoleucin 3,16 g aktiv substans; leucin 4,39 g aktiv substans
cresnisol n10e infusionsvätska, lösning
baxter medical ab - alanin; arginin; asparaginsyra; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; kaliumklorid; leucin; lysinacetat; magnesiumkloridhexahydrat; metionin; natriumacetattrihydrat; natriumglycerofosfat, hydratiserat; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - glycin 4,39 g aktiv substans; histidin 3,77 g aktiv substans; glutaminsyra 3,16 g aktiv substans; arginin 6,2 g aktiv substans; alanin 9,16 g aktiv substans; valin 4,05 g aktiv substans; leucin 4,39 g aktiv substans; isoleucin 3,16 g aktiv substans; asparaginsyra 1,83 g aktiv substans; lysinacetat 7,02 g aktiv substans; magnesiumkloridhexahydrat 1,12 g aktiv substans; natriumacetattrihydrat 2,89 g aktiv substans; treonin 3,16 g aktiv substans; natriumglycerofosfat, hydratiserat 4,78 g aktiv substans; tryptofan 1,06 g aktiv substans; tyrosin 0,16 g aktiv substans; metionin 3,16 g aktiv substans; fenylalanin 4,39 g aktiv substans; kaliumklorid 2,98 g aktiv substans; prolin 3,77 g aktiv substans; serin 2,5 g aktiv substans
cresnisol n18 infusionsvätska, lösning
baxter medical ab - alanin; arginin; asparaginsyra; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; leucin; lysinacetat; metionin; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - alanin 16 g aktiv substans; treonin 5,53 g aktiv substans; serin 4,38 g aktiv substans; prolin 6,6 g aktiv substans; fenylalanin 7,68 g aktiv substans; tyrosin 0,28 g aktiv substans; valin 7,08 g aktiv substans; lysinacetat 12,2 g aktiv substans; tryptofan 1,85 g aktiv substans; arginin 10,9 g aktiv substans; asparaginsyra 3,2 g aktiv substans; glutaminsyra 5,53 g aktiv substans; glycin 7,68 g aktiv substans; histidin 6,6 g aktiv substans; isoleucin 5,53 g aktiv substans; leucin 7,68 g aktiv substans; metionin 5,53 g aktiv substans